Ultragenyx, Kyowa Kirin Reports 64-Week Results For Crysvita From Phase 3 Study For X-Linked Hypophosphatemia: 'Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy'
Benzinga Newsdesk